> HDL Biology Archive <

ABCA1 implicated in control of ß-cell cholesterol homeostasis

March 2007 - New data indicate that ABCA1 (ATP-binding cassette transporter subfamily A member 1), which facilitates the delivery of cholesterol from cells to lipid-poor apolipoprotein A-I in the extracellular space, plays a key role in ß-cell cholesterol homoeostasis and insulin secretion.
Read more...

New evidence suggests a role for HDL in inflammatory and coagulation processes

March 2007 - A study reported in the Journal of Clinical Investigation shows that HDL is enriched in proteins involved in complement activation, as well as protease inhibitors, supporting the concept that HDL plays a key role in the regulation of inflammation, coagulation and tissue remodelling.
Read more...

High HDL reduces the risk of recurrent venous thromboembolism

March 2007 - People with high levels of HDL and apolipoprotein A-I, the main lipoprotein in HDL, have a lower risk of recurrent venous thromboembolic episodes.
Read more...

ApoB/HDL cholesterol ratio is the strongest predictor of cardiovascular risk

October 2006 - The ratio of apolipoprotein B, a marker of atherogenic lipoproteins, to HDL cholesterol may be a stronger predictor of cardiovascular risk and determining the need for lipid-modifying therapy.
Read more...

Potential antiatherogenic role of SR-BI in extrahepatic tissues

October 2006 - SR-B1, an HDL receptor that promotes selective uptake of HDL, may exert an antiatherogenic role in both hepatic and extrahepatic tissues.
Read more...

Raising HDL cholesterol levels may reduce the risk of myocardial ischaemia/reperfusion injury

September 2006 - Raising HDL cholesterol levels could prove beneficial in patients at high risk of acute myocardial ischaemia.
Read more...

Link between hyperhomocysteinaemia, HDL cholesterol and atherosclerosis

September 2006 - Two recent studies provide evidence for a link between plasma homocysteine, HDL cholesterol and cardiovascular disease.
Read more...

Patients with ACS and low HDL cholesterol levels are at increased risk

September 2006 - Patients with acute coronary syndrome and low baseline levels of HDL cholesterol are at increased risk of death and adverse cardiac events, irrespective of LDL cholesterol levels.
Read more...

Enhanced ability of HDL to promote cholesterol efflux in CETP-deficient subjects

May 2006 - Genetic deficiency or inhibition of cholesteryl ester transfer protein (CETP) leads to a marked increase in HDL cholesterol levels, in particular increasing the level of large HDL-2 particles with enhanced ability to promote cholesterol efflux.
Read more...

Changes in HDL and LDL particle subclasses with gemfibrozil predict coronary events

March 2006 - New data from the Veterans Affairs HDL Trial show that fibrate therapy produces favourable changes in the lipoprotein profile of patients.
Read more...

Importance of assessing HDL cholesterol in primary care setting

March 2006 - Subjects with elevated levels of HDL cholesterol had a significantly lower risk of coronary events, according to a retrospective primary care cohort study.
Read more...

Association of dyslipoproteinaemia and venous thrombosis

August 2005 - Venous thrombosis in younger men (<55 years) is associated with an increase in the ratio of atherogenic to atheroprotective apolipoproteins, indicative of increased cardiovascular risk.
Read more...

Effects of extended-release niacin on lipoprotein profile and inflammatory markers

September 2006 - Addition of extended-release niacin (nicotinic acid) to existing statin therapy improves the distribution of lipoprotein particle sizes and inflammatory markers, suggesting potential for atheroprotection.
Read more...

Intestinal ABCA1 is a potential target for raising HDL cholesterol

September 2006 - GW3965, a synthetic liver X receptor agonist, may have potential as a new tool for raising HDL cholesterol levels, avoiding systemic side effects.
Read more...

Extrahepatic tissues also have a role in maintaining HDL cholesterol levels

September 2006 - Both extrahepatic and hepatic tissues play a role in maintaining HDL cholesterol levels. Targeting factors involved in HDL remodelling in both of these tissues could provide novel approaches to raising HDL cholesterol.
Read More...

Enhanced ability of HDL to promote cholesterol efflux in CETP-deficient subjects

May 2006 - Genetic deficiency or inhibition of cholesteryl ester transfer protein (CETP) leads to a marked increase in HDL cholesterol levels, in particular increasing the level of large HDL-2 particles with enhanced ability to promote cholesterol efflux.
Download article...

Changes in HDL and LDL particle subclasses with gemfibrozil predict coronary events

March 2006 - New data from the Veterans Affairs HDL Trial show that fibrate therapy produces favourable changes in the lipoprotein profile of patients.
Download article...

Importance of assessing HDL cholesterol in primary care setting

March 2006 - Subjects with elevated levels of HDL cholesterol had a significantly lower risk of coronary events, according to a retrospective primary care cohort study.
Download article...

Association of dyslipoproteinaemia and venous thrombosis

August 2005 - Venous thrombosis in younger men (<55 years) is associated with an increase in the ratio of atherogenic to atheroprotective apolipoproteins, indicative of increased cardiovascular risk.
Download article...

> News Archive <

HDL cholesterol: an independent risk factor for progression of subclinical cardiovascular disease

Data from the Atherosclerosis Risk in Communities (ARIC) study show that HDL cholesterol may be an important modifiable risk factor for the progression of subclinical cardiovascular disease, as reported at ACC 2007.
Download article...

Low HDL cholesterol is common in patients with non-ST-segment elevation acute coronary syndromes

Data from the CRUSADE initiative show that more than 50% of patients with non-ST-segment elevation acute coronary syndromes have low HDL cholesterol (<40 mg/dL), as reported at ACC 2007.
Download article...

Over 70% of statin-treated patients have low HDL cholesterol

Two-thirds of statin-treated patients with or at risk of coronary heart disease have low HDL cholesterol. This patient group represents a large unmet opportunity for further CHD prevention.
Download article...

Disappointing results with major studies with torcetrapib

Results from ILLUSTRATE and RADIANCE failed to demonstrate any benefit on progression of atherosclerosis with torcetrapib administered in combination with atorvastatin, despite substantial increases in HDL cholesterol.
Download article...

Results of METEOR Trial: rosuvastin in low-risk patients

Rosuvastatin slowed progression of atherosclerosis at 2 years in people with early signs of carotid artery disease and at low-risk of coronary heart disease (CHD).
Download article...

HDL infusion improves plaque characteristics: results of ERASE trial

Short-term infusion of CSL-111, a reconstituted HDL, produced significant improvement in plaque characteristics compared with placebo.
Download article...

Mixed results with LY518674, novel therapy for lipid disorders

LY518674, a novel, potent peroxisome proliferator- activated receptor alpha (PPAR-alpha) agonist, showed no advantages compared with fenofibrate, in clinical studies.
Download article...

HDL a key focus of EAS Congress, June 2007

The relevance of HDL to atherosclerosis is a major emphasis of the upcoming 76th Congress of the European Atherosclerosis Society, Helsinki, June 10-13, 2007. There will be a plenary session and an official EAS HDL Satellite Symposium focusing on HDL and cardiovascular disease. For further information, see the meeting website at
www.eas2007.fi

Low apolipoproteinA-II is a predictor of coronary heart disease

Apolipoprotein II, the second main protein in HDL, is inversely related to risk of coronary heart disease, according to new data presented at the American Heart Association Scientific Sessions.
Download article...

Should measurement of ApoB/ApoA1 ratio be incorporated into clinical guidelines?

The ratio of apolipoprotein B/apolipoprotein A-I (i.e., atherogenic to atheroprotective lipoproteins) was the strongest predictor of cardiovascular risk, according to pooled analyses of two recent major statin studies, presented at the American Heart Association Scientific Sessions.
Download article...

High HDL cholesterol improves outcome following drug-eluting stent implantation

High HDL cholesterol levels are protective against major adverse cardiac events within one year of drug-eluting stent implantation, according to data presented at the American Heart Association Scientific Sessions.
Download article...

Apolipoprotein A-I mimetic improves HDL anti-inflammatory function

Administration of the apolipoprotein A-I mimetic peptide D-4F improves anti-inflammatory activity of HDL in patients at high risk of coronary heart disease, suggesting therapeutic potential for attenuation of atherosclerosis.
Download article...

First report of SR-B1 mutation in man influencing HDL cholesterol levels

Researchers from the Academic Medical Center, Amsterdam, The Netherlands presented the first evidence of a scavenger receptor class B1 (SR-B1) mutation in man. SR-B1 is a hepatic receptor that promotes selective uptake and removal of HDL from the plasma, and is therefore important in protecting against atherosclerosis.
Download article...

Low HDL cholesterol is a predictor of stroke

Data from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study show that low HDL cholesterol is an important predictor of risk of stroke in patients with recent stroke or transient ischaemic attack.
Download article...

Reconstituted HDL improves endothelial function in type 2 diabetes

Infusion of reconstituted HDL exerts direct beneficial effects on the arterial wall in patients with type 2 diabetes, providing support for therapeutic strategies that increase the vasodilatory properties of HDL.
Download article...

MK-0524 reduces flushing with prolonged-release nicotinic acid

Co-administration of MK-0524, an investigational DP1-receptor antagonist, with prolonged-release (PR) nicotinic acid significantly reduces flushing, a common side effect of this HDL cholesterol-raising agent that often leads to treatment discontinuation.
Download article...

ILLUMINATE Trial Terminated

The ILLUMINATE trial was a Pfizer-funded study designed to test whether the experimental cholesteryl ester transfer protein (CETP) inhibitor drug, torcetrapib, reduces cardiovascular events.
Download article...